Ciclosporin intravenous - Maas Biolab/NeuroVive

Drug Profile

Ciclosporin intravenous - Maas Biolab/NeuroVive

Alternative Names: CicloMulsion; Ciclosporin-A; Cyclosporin - Maas Biolab; Cyclosporin-A; Mitogard; Neuro-STAT®; NeuroSTAT

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maas Biolab; NeuroVive Pharmaceutical
  • Developer Defense Threat Reduction Agency; Maas Biolab; NeuroVive Pharmaceutical; Skane University Hospital; Walter Reed Army Institute of Research
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Cyclophilin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Brain injuries
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries
  • No development reported Amyotrophic lateral sclerosis; Poisoning
  • Discontinued Acute kidney injury; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Intrathecal)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Poisoning in USA (IV, Injection)
  • 31 Oct 2017 NeuroVive signs collaboration agreement with University of Florida to conduct biomarker research to support development of ciclosporin intravenous for Brain injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top